Patent classifications
C07D319/06
FE/CU-MEDIATED KETONE SYNTHESIS
Provided herein are methods for preparing ketone-containing organic molecules. The methods are based on novel iron/copper-mediated (“Fe/Cu-mediated”) coupling reactions. The Fe/Cu-mediated coupling reaction can be used in the preparation of complex molecules, such as halichondrins and analogs thereof. In particular, the Fe/Cu-mediated ketolization reactions described herein are useful in the preparation of intermediates en route to halichondrins.
##STR00001##
FE/CU-MEDIATED KETONE SYNTHESIS
Provided herein are methods for preparing ketone-containing organic molecules. The methods are based on novel iron/copper-mediated (“Fe/Cu-mediated”) coupling reactions. The Fe/Cu-mediated coupling reaction can be used in the preparation of complex molecules, such as halichondrins and analogs thereof. In particular, the Fe/Cu-mediated ketolization reactions described herein are useful in the preparation of intermediates en route to halichondrins.
##STR00001##
Perfluoro copolymers
Provided herein are perfluoro copolymers of a perfluoro dioxole monomer, a perfluoro dioxane monomer, and an optional perhalo monomer. Methods of making the perfluoro copolymers and methods of using the perfluoro copolymers are also disclosed.
Perfluoro copolymers
Provided herein are perfluoro copolymers of a perfluoro dioxole monomer, a perfluoro dioxane monomer, and an optional perhalo monomer. Methods of making the perfluoro copolymers and methods of using the perfluoro copolymers are also disclosed.
PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS
The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.
PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS
The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.
Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
- Steven John Taylor ,
- John Robert Proudfoot ,
- Mi-Jeong Kim ,
- Kathleen Nudel ,
- Timothy F. Briggs ,
- Afrand Kamali Sarvestani ,
- Leonard Buckbinder ,
- Bernard Lanter ,
- Ferdinand Edward Massari ,
- Koji Yasuda ,
- Spencer Cory Peck ,
- Cheri Snedeker ,
- Diana Le ,
- Jessica Alexander ,
- Anna Liang ,
- Dinara Gunasekera ,
- David Arthur Berry ,
- John Patrick Casey, Jr.
Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.
PERFLUORO COPOLYMERS
Provided herein are perfluoro copolymers of a perfluoro dioxole monomer, a perfluoro dioxane monomer, and an optional perhalo monomer. Methoda of making the perfluoro copolymers and methods of using the perfluoro copolymers are also disclosed.
PERFLUORO COPOLYMERS
Provided herein are perfluoro copolymers of a perfluoro dioxole monomer, a perfluoro dioxane monomer, and an optional perhalo monomer. Methoda of making the perfluoro copolymers and methods of using the perfluoro copolymers are also disclosed.
SIMPLE ASTATINE CONCENTRATION METHOD
In order to produce high yields of astatine-211 without contamination of chloride ions, provided is a method for producing astatine-211, including (1) a step of generating astatine-211 by irradiating bismuth with α rays; (2) a step of heating the astatine-211 generated in step (1) to vaporize; (3) a step of cooling the astatine-211 that has been vaporized in step (2) and collecting the astatine-211 with a volatile and polar solvent to obtain an astatine-211 solution; (4) a step of adding a weak acid salt to the astatine-211 solution obtained in step (3) to obtain an astatine-211 solution containing the weak acid salt; and (5) a step of removing the solvent from the astatine-211 solution containing the weak acid salt obtained in step (4).